The Oxford vaccine manager said the results of the final phase trial of the Oxford / AstraZeneca COVID-19 vaccine candidate are “complicated” and more work needs to be done to ensure that the initial half-dose of the vaccine provides more protection.
Results from a phase III trial of the candidate vaccine showed that it was 90% effective if given at half the dose and then at the full dose or 62% if given at two. full doses.
“These 90% are a delicate result. So when we give half the dose as the first dose (that means), we have a vaccine available. And then… after the second dose, we see 90% protection ”Pollard, director of the Andrew Oxford Vaccine Group, told BBC TV.
“I think this is a really exciting and intriguing result that we need to dig deeper into,” he said.
(Except for the title, this story was not edited by NDTV staff and posted from a syndicated feed.)